Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
1.
Pan Afr Med J ; 35(Suppl 2): 134, 2020.
Article in French | MEDLINE | ID: covidwho-926732

ABSTRACT

Hydroxychloroquine is an agent used as a treatment but also considered as a prophylaxis for SARS-CoV-2 infection. We report the case of a patient who developed COVID-19 while on hydroxychloroquine for mixed connectivitis associated with spondyloarthritis. Although more work is needed before any conclusions can be drawn, this raises questions about the protective role of this drug against infection. Are they really protected against COVID-19 or will they develop pauci-symptomatic forms?


Subject(s)
Antirheumatic Agents/therapeutic use , Antiviral Agents/therapeutic use , Betacoronavirus/drug effects , Coronavirus Infections/drug therapy , Etanercept/therapeutic use , Hydroxychloroquine/therapeutic use , Mixed Connective Tissue Disease/drug therapy , Pneumonia, Viral/drug therapy , Skin Diseases, Viral/etiology , Spondylarthropathies/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Urticaria/etiology , Antirheumatic Agents/adverse effects , COVID-19 , Coronavirus Infections/complications , Disease Susceptibility , Etanercept/adverse effects , Humans , Male , Mixed Connective Tissue Disease/complications , Pandemics , Pneumonia, Viral/complications , SARS-CoV-2 , Spondylarthropathies/complications , Tumor Necrosis Factor-alpha/adverse effects , Young Adult , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL